The core objective of the work being carried out at the Center for Molecular Signaling (PZMS) is the identification and validation of membrane proteins as novel targets in the pharmacological treatment of genetic disorders that disrupt homoeostasis in humans.

The teams at PZMS study the pathophysiology of human diseases that can disrupt neurohumoral control pathways and thus impair the onset of puberty, cause cardiac dysfunction or compromise bone development and growth. The research is focused on identifying and characterizing new pharmacological targets, particularly those membrane proteins and membrane protein complexes that act as molecular switches within the signal processing networks in plasma membrane or intracellular membrane systems. PZMS is therefore home to working groups in the fields of preclinical medicine (biochemistry and molecular biology, cell biology) and clinical-theoretical medicine (pharmacology and toxicology).